China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced its intention to invest in and gradually acquire a 100% stake in its compatriot firm, Transcend Biomedical (Suzhou) Co., Ltd. The investment will be made in installments, with the first phase amounting to RMB 150 million (USD 20.7 million). This strategic move is aimed at establishing BCHT as a key player in the mRNA research and development (R&D) space.
Investment in mRNA Technology and Licensing Deal
Transcend Biomedical, valued at RMB 701.1 million (USD 97 million) in terms of net assets as of March 31, 2023, has already made significant strides in the mRNA sector. In May 2021, the company struck a non-exclusive licensing deal with Acuitas, securing rights to the latter’s lipid nanoparticle (LNP) delivery technology to support the development of its mRNA vaccines. This technology is crucial for the efficient delivery of mRNA vaccines and has positioned Transcend as a competitive player in the mRNA therapeutics market.
BCHT’s Expansion into mRNA R&D
The acquisition of Transcend Biomedical aligns with BCHT’s ambition to expand its presence in the mRNA R&D space. By acquiring a 100% stake in Transcend, BCHT will gain access to cutting-edge mRNA technology and expertise, enhancing its capabilities in developing innovative mRNA-based therapies and vaccines.-Fineline Info & Tech
